Imatinib Mesylate

Description

Imatinib Mesylate is used to treat and prevent the growth of certain types of cancers of the blood cells, stomach, intestine, bone marrow, and skin.

Side effects

Major & minor side effects for Imatinib Mesylate

  • Diarrhea
  • Nausea and Vomiting
  • Mouth sores
  • Loss of appetite
  • Altered sense of taste
  • Heartburn and indigestion
  • Joint pain, stiffness, and swelling
  • Burning or tingling sensation of skin
  • Difficulty in falling or staying asleep
  • Skin rash, hives, or itching
  • Hair loss or thinning of the hair
  • Swelling around the eyes
  • Swelling or the hands, feet, ankle, and lower legs
  • Severe breathing difficulty
  • Fast/irregular heart beat
  • Presence of blood in cough
  • Yellowing of skin and eyes
  • Unusual bleeding or bruising
  • Abdominal pain or bloating
  • Bloody stool

Uses of Imatinib Mesylate

What is it prescribed for?

  • Chronic myelogenous leukemia (CML)
  • Acute lymphoblastic Leukemia (ALL)
  • Myeloproliferative disorder
  • Myelodysplastic disease
  • Systemic mastocytosis
  • Hypereosinophillic syndrome
  • Chronic eosinophillic leukemia
  • Dermatofibrosarcoma protuberans
  • Gastrointestinal stromal tumor
Read More
Concerns

Commonly asked questions

  • Onset of action
    The amount of time taken by this medicine to show its effect is subject to vary based on the intended use.
  • Duration of effect
    The amount of time for which this medicine remains effective in the body is subject to vary based on the intended use and duration of use.
  • Safe with alcohol?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?
    No habit forming tendencies were reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary and the potential benefits outweigh the risks involved. Your doctor will determine the best course of treatment after assessing the clinical condition.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. Your doctor may advise you to discontinue breastfeeding or to discontinue the drug based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to imatinib or any other inactive ingredients present along with it.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary and the potential benefits outweigh the risks involved. Your doctor will determine the best course of treatment after assessing the clinical condition.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. Your doctor may advise you to discontinue breastfeeding or to discontinue the drug based on your clinical condition.
General warnings

Gastrointestinal disorders

This medicine should be used with caution in patients having a pre-existing disorder of the stomach or the intestine due to the increased risk of worsening of the patient's condition. Replacement with a suitable alternative may be necessary based on the clinical condition.

Hypothyroidism

This medicine should be used with caution in patients having a low level of thyroid hormone due to the increased risk of worsening of the patient's condition. Close monitoring of thyroid hormones is recommended for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Use in the elderly

This medicine should be used with caution in the elderly patients due to the increased risk of severe adverse effects.

Other medicines

Since Imatinib Mesylate may interact with many other medicines and may cause severe adverse effects, it is advised that you report the use of all other medicines including herbs and supplements to the doctor before beginning treatment with Imatinib Mesylate.

Live attenuated vaccine

Report the administration of a live attenuated vaccine (smallpox, BCG, influenza, measles, rubella, etc.) to the doctor before treatment with Imatinib Mesylate is initiated. Since Imatinib Mesylate may alter the effects of the vaccines, your doctor may advise you to postpone therapy with the medicine based on your clinical condition.

Heart and blood vessel disorder

This medicine should be used with caution in patients having a disorder of the heart or blood vessels due to the increased risk of worsening of the patient's condition.

Fluid retention and edema

This medicine should be used with caution in patients suffering from fluid retention or edema due to the increased risk of worsening of the patient's condition.

Growth retardation

This medicine should be used with caution in children due to the increased risk of growth retardation. Close monitoring of growth parameters is advised during treatment with this medicine.

Dizziness and blurring of vision

Use of this medicine may cause dizziness and blurring of vision. Hence, it is advised that you do not perform any activities that require high mental alertness such as driving a vehicle or operating heavy machinery during treatment with this medicine.

Internal bleeding or hemorrhage

This medicine should be used with caution due to the increased risk of internal bleeding or hemorrhages. Any symptoms such as unusual bleeding or bruising, black or tarry stools, vomiting up blood, etc. should be reported to the doctor on priority. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Risk of infections

Use of this medicine may weaken the immune system and may make you more vulnerable to infections. It is advised that you avoid coming in contact with people suffering from an infection while taking this medicine.

Missed Dose

Take the missed dose as soon as you remember. If it is almost time for the next scheduled dose, then the missed dose can be skipped. Contact your doctor for further instructions if you miss more than one scheduled dose of this medicine.

Overdose

Contact your doctor immediately if an overdose with this medicine is suspected. Symptoms may include nausea, vomiting, diarrhea, skin allergies, tiredness, fever, etc.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Carbamazepine

Cisapride

Clarithromycin

Erythromycin

Ketoconazole

Pimozide

Warfarin

Colchicine

Phenobarbital

BCG vaccine

Dexamethasone

Etanercept

Disease interactions

Heart and blood vessel disorder

This medicine should be used with caution in patients having a disease of the heart or the blood vessels due to the increased risk of worsening of the patient's condition. Close monitoring of heart function is recommended for such patients. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.

Fluid Retention and edema

This medicine should be used with caution in patients having fluid retention disorders due to the increased risk of worsening of the patient's condition. Appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary based on the clinical condition.

Bone marrow suppression

This medicine should be used with caution in patients having conditions like thrombocytopenia, agranulocytosis, anemia, or bone marrow suppression due to the increased risk of worsening of the patient's condition. A complete blood count should be performed before initiating treatment with this medicine. Close monitoring of blood counts is recommended during treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Liver/kidney impairment

This medicine should be used with caution in patients suffering from a disease of the liver or the kidneys due to the increased risk of severe side effects. Appropriate dose adjustments and frequent clinical monitoring are advised in such cases. Replacement with a suitable alternative may be required based on the clinical condition.
Food interactions
Consumption of grapefruit or grapefruit juice is not recommended during treatment with this medicine due to the increased risk of severe adverse effects.
Lab interactions
Information not available.
Take Imatinib Mesylate exactly as prescribed by the doctor. Do not take in larger or smaller quantities than recommended. Do not take this medicine on an empty stomach. You may require frequent blood tests and liver function tests while taking this medicine. You may also require frequent followups with your doctor to check the progress of treatment. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

To be taken with food

To be taken as instructed by doctor

May cause sleepiness

How it works
This medicine works by inhibiting the actions of certain abnormal proteins that cause the cancer cells to multiply. This helps in stopping the growth and spread of cancer.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

BCR-ABL tyrosine kinase inhibitors

Schedule

Schedule H

Imatinib: MedlinePlus Drug Information [Internet]. Medlineplus.gov. 2017 [cited 13 September 2017]. Available from:

https://medlineplus.gov/druginfo/meds/a606018.html

DailyMed: Imatinib Mesylate tablet, film coated [Internet]. Dailymed.nlm.nih.gov. 2017 [cited 13 September 2017]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0291eca5-7a1d-4a79-30be-252224d96509

Imatinib mesylate [Internet]. Pubchem.ncbi.nlm.nih.gov. 2017 [cited 13 September 2017]. Available from:

https://pubchem.ncbi.nlm.nih.gov/compound/123596

Imatinib - DrugBank [Internet]. Drugbank.ca. 2017 [cited 13 September 2017]. Available from:

https://www.drugbank.ca/drugs/DB00619

[Internet]. Ebi.ac.uk. 2017 [cited 13 September 2017]. Available from:

https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL941

Imatinib (Glivec) | Cancer in general | Cancer Research UK [Internet]. Cancerresearchuk.org. 2017 [cited 13 September 2017]. Available from:

http://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/imatinib

Imatinib Mesylate [Internet]. National Cancer Institute. 2017 [cited 13 September 2017]. Available from:

https://www.cancer.gov/about-cancer/treatment/drugs/imatinibmesylate

[Internet]. 2017 [cited 14 September 2017]. Available from:

https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/gleevec_tabs.pdf

How will this medicine affect me?

Consult top doctors online and get an answer now
Chat now
Chat now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now
Book now
Something doesn’t feel right?
Report an error

Information on this page was last updated on 15 Sep 2017

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.